A peptide calculator does one job well: arithmetic. Type in a vial’s labeled mass, the water you added, and a target dose, and it tells you how many units to draw. What it cannot do, and what most of the apps ranking for this term don’t admit, is tell you whether the number it just handed you has ever been tested in a person. For a handful of peptides, that number traces to a specific clinical trial. For most of the compounds people calculate doses for, it traces to nothing at all.
What the math is
The calculation itself is simple division. Vial mass divided by diluent volume gives concentration. Target dose divided by concentration gives the injection volume, which then converts to units on an insulin syringe.
The number is only as good as its inputs. For an FDA-approved peptide dispensed by a pharmacy, the label is regulated and the concentration is what it says. For a peptide bought from a research-chemical vendor, the labeled mass is a claim nobody outside that vendor has independently checked. The calculator will still produce a confident-looking figure either way. It has no way to know which kind of vial you gave it.
Doses with a real trial behind them
Three peptides that show up in calculator apps have a dose that traces to an actual interventional program rather than a forum consensus.
Semaglutide. The approved weekly maintenance dose for chronic weight management is 2.4 mg, reached through a titration schedule. In the STEP 1 trial, 1,961 adults with overweight or obesity were randomized to that regimen or placebo for 68 weeks, and the semaglutide group lost 14.9% of body weight against 2.4% for placebo.[1]
Tirzepatide. Its approved maintenance doses of 10 mg or 15 mg weekly were reached only after a 20-week dose-escalation period, the schedule evaluated in the SURMOUNT-1 trial, which assigned adults with obesity to that regimen or to placebo.[2] The maintenance doses calculators list for tirzepatide are the ones this trial tested. The exact starting-dose figure that gets repeated online isn’t something this abstract states, so confirm it against the prescribing label rather than a calculator app.
Tesamorelin. The approved regimen for HIV-associated lipodystrophy is a fixed 2 mg once daily. Falutz and colleagues randomized 412 patients with HIV and abdominal fat accumulation to that exact dose or placebo for 26 weeks, and visceral fat fell 15.2% in the treated group against a 5.0% increase with placebo.[3]
Where three calculator defaults come from
Peptide | Calculator default | Trial behind it | N |
|---|---|---|---|
Semaglutide | 2.4 mg weekly | STEP 1 | 1,961 |
Tirzepatide | 10 or 15 mg weekly | SURMOUNT-1 | 2,539 |
Tesamorelin | 2 mg daily | Falutz et al. 2007 | 412 |
Dose figures a calculator app will accept without asking.
These three have something else in common. Nobody needs a phone app to hit these doses, because a pharmacy already measured them into a pen. The calculator earns its keep only where that oversight is absent, which is exactly where its numbers get shakier.
Bottom line: a calculator can reproduce a trial’s dose perfectly. It cannot tell you whether a trial produced that dose in the first place.
The peptides where the number comes from nowhere
Type “BPC-157” or “TB-500” into most peptide calculators and it will hand you a number just as confidently as it hands you the semaglutide dose. The evidence behind that number is not remotely comparable.
BPC-157. A 2025 systematic review by Vasireddi and colleagues searched the literature back to 1993 and found 36 total studies, 35 of them preclinical. The lone human study was a retrospective case series: 12 patients received a single intraarticular BPC-157 injection for chronic knee pain, and 7 later recalled feeling better six months on, with no control group and no clinical safety data collected.[4] That is the entire human dosing record for a peptide with an active online calculator ecosystem.
35 of 36 published BPC-157 studies were preclinical, in rodents rather than people PMID 40756949
Thymosin beta-4 (TB-500). Philp and Kleinman’s review of the peptide’s tissue-repair evidence describes animal work in dermal, corneal, and cardiac injury models as the foundation that later human trials were built on, not a body of completed human dosing data in its own right.[5] The dosing figures that circulate for TB-500 as a subcutaneous injection for tendon and joint recovery are downstream of that animal foundation rather than any pharmacokinetic study in people. Readers who want the fuller record on that peptide can find it in our separate TB-500 evidence review.
GHK-Cu belongs in this conversation too, and here honesty means saying what this pass of research could not pin down. The compound’s calculators list injectable systemic protocols, but confirming exactly what human evidence exists for that route (versus the topical, skin-focused studies GHK-Cu is known for) needs a dedicated look, which we’ve done separately. Nothing here should be read as confirming or denying that gap.
Where the middle tier lands
Ipamorelin and MOTS-c occupy a different category still: real human data exists, but it answers a narrower question than the calculator implies.
Human pharmacology data exists for the growth-hormone secretagogue ipamorelin, tested as single escalating doses in healthy male volunteers by Gobburu and colleagues, not for the combined daily-stacking regimens of ipamorelin and CJC-1295 that anti-aging clinics promote.[6] The trial used five infusion levels, from 4.21 to 140.45 nmol/kg, each a single 15-minute infusion, with a terminal half-life of about 2 hours. That is real human pharmacology data. It is not a daily subcutaneous stacking protocol with a second peptide layered on top.
MOTS-c has a similar mismatch, but of a different kind. Most human MOTS-c research doesn’t administer the peptide at all. Von Walden and colleagues randomized healthy adults to endurance cycling, resistance training, or a control condition, then measured how the body’s own circulating MOTS-c changed afterward.[7] That’s a study of what exercise does to a person’s existing MOTS-c, not what injecting MOTS-c would do to a person.
The distinction is the same one that trips up any correlation read backward: more firefighters show up at bigger fires, but dispatching extra firefighters to a small fire won’t make it grow. An observed correlation between a molecule and an outcome says nothing about what happens if you administer that molecule from the outside.
What a calculator’s precision hides
A calculator that spits out “0.24 mL” is doing exactly what a calculator should do. The number looks authoritative because it has two decimal places. That has nothing to do with whether the substance behind it has ever been tracked for safety in a human trial.
Contrast that with what a real trial monitors. STEP 1’s protocol tracked adverse events closely enough to report that gastrointestinal events, mainly nausea and diarrhea, caused 4.5% of the semaglutide group to discontinue treatment, versus 0.8% on placebo.[1] That level of systematic surveillance, a defined population, a comparator arm, a prespecified list of events to watch for, is what “safety data” means. Nothing resembling it exists for a peptide bought from a compounding shortcut and dosed by a phone app.
The gap that matters: a trial-tracked side-effect rate is a number generated by watching thousands of people closely. A forum-sourced dosing protocol is a number generated by nobody watching anyone.
What a calculator cannot replace
For the three approved peptides in this article, a calculator is close to redundant. Pharmacies dispense semaglutide, tirzepatide, and tesamorelin in pre-measured pens precisely so a patient never needs to compute a dose by hand.
For everything else on this list, the calculator is solving the wrong problem: it computes an arithmetic answer while the real gap is confirming that the vial contains what its label claims, at the concentration the label states, a job for a lab or a clinician rather than an app. No calculator, however precise its output, performs that check.
A shorter filter than the calculator gives you
Before typing anything into a dosing app, three questions do more work than the output ever will:
Is there an approved indication? If yes, a pharmacist has already solved the arithmetic problem for you, correctly, with a regulated product.
Does the dose trace to a named trial, or to a forum consensus? Semaglutide, tirzepatide, and tesamorelin pass this test. Most research-chemical peptides do not, and the calculator has no way to flag the difference.
Has anyone independently confirmed what’s in the vial? A confident number computed from an unverified label is still an unverified label, just with more decimal places.
None of those questions can be answered by a calculator, no matter how good its interface is. That is the real dividing line running through this whole category: three peptides where the math and the medicine both check out, and a longer list where the math checks out and the medicine was never run.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine, 2021.
Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine, 2022.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England journal of medicine, 2007.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025.
Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide.. Annals of the New York Academy of Sciences, 2010.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharmaceutical research, 1999.
Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.. Journal of applied physiology (Bethesda, Md. : 1985), 2021.
